Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jan 20, 2026 (9 months ago)

Max Packaging Antibacterial Towelette

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Max Packaging Antibacterial Towelette (Benzalkonium Chloride 0.13%), 1 towelette, 4x7, Max Packaging, Made in the USA, NDC 59647-750-01

Affected NDC 59647-0750-01

Compare with the code on your package — it is the most precise check available.

Drug: Benzalkonium

Recalling firm
Acme United Corporation
NDC code
59647-750-01
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0363-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Benzalkonium recalls

See all
Class II · Moderate risk

Revitaderm Wound Care

CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Ongoing cGMP deviation Blaine Labs Inc NDC 63347-120-02 D-0699-2026
Class I · High risk

Revitaderm Wound Care Gel

Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp

Ongoing Microbial contamination Blaine Labs Inc NDC 63347-120-02 D-0692-2026

Other recalls by Acme United Corporation

All 2026 recalls
Class II · Moderate risk

Dynarex

CGMP Deviations

Ongoing cGMP deviation Acme United Corporation NDC 67777-245-04 D-0376-2026
Class II · Moderate risk

Dynarex

CGMP Deviations

Ongoing cGMP deviation Acme United Corporation NDC 67777-245-01 D-0375-2026